TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04798222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
Study: NCT05866783

Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrencePrognosticScore
Description: Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling

Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrencePrognosticScore
Description: Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling

Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrenceDiagnosticScore
Description: Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling

Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrenceDiagnosticScore
Description: Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
Study: NCT05239208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement (ONS) Group
Description: Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Dietary counseling
Study: NCT04916431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-6231
Description: Sterile frozen liquid dispersion for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-6231
Description: Sterile frozen liquid dispersion for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-6231
Description: Sterile frozen liquid dispersion for injection
Study: NCT06243094

Intervention type: DRUG
Intervention: Antibiotic
Description: All antibiotic therapy characteristics are monitored.

Intervention type: DRUG
Intervention: Antibiotic
Description: All antibiotic therapy characteristics are monitored.
Study: NCT05848609

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Geriatric Assessment
Description: Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
Study: NCT05769764

Intervention type: OTHER
Intervention: Archival tissue specimen and immunohistochemistry staining
Description: This is a non-interventional study and no intervention will be administered.

Intervention type: OTHER
Intervention: Archival tissue specimen and immunohistochemistry staining
Description: This is a non-interventional study and no intervention will be administered.

Intervention type: OTHER
Intervention: Archival tissue specimen and immunohistochemistry staining
Description: This is a non-interventional study and no intervention will be administered.

Intervention type: OTHER
Intervention: Archival tissue specimen and immunohistochemistry staining
Description: This is a non-interventional study and no intervention will be administered.
Study: NCT05744596

Intervention type: OTHER
Intervention: Incisura biopsy analysis
Description: a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
Study: NCT05043805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: add on therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: add on therapy
Study: NCT05894252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Interventions
Description: Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free.
Study: NCT05364216

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
Study: NCT04829942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive health behavior
Description: Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
Study: NCT05765292

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Study: NCT04798222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
Study: NCT05364216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
Study: NCT05364216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The assessment of cognitive function
Description: Participants were assessed for MMSE and MoCA at the same period as the group C
Study: NCT04798222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.
Study: NCT06352697

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lysate (postbiotic and metabiotc)
Description: Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06260605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Nursing students learning about diabetes complications
Study: NCT06345599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
Description: GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
Description: Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
Study: NCT06189248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness intervention
Description: Teaching personal and social resourcefulness skills.
Study: NCT05031572

Intervention type: OTHER
Group type: OTHER
Intervention: dietary intervention
Description: Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis

Intervention type: OTHER
Group type: OTHER
Intervention: dietary intervention
Description: Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
Study: NCT04489537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MarzAA
Description: A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MarzAA
Description: A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
Study: NCT06376929

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral carbohydrate containing fluid
Description: administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral carbohydrate containing fluid
Description: administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
Study: NCT06195098

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional educational intervention
Description: The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
Study: NCT04667052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 64304500
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 64304500
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
Study: NCT04682678

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Implantation of electrodes for Spinal cord stimulation
Description: The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of electrodes for Spinal cord stimulation
Description: The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
Study: NCT05263921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332/ritonavir under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
Study: NCT05451992

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SuperFood
Description: The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
Study: NCT05384639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-task Group
Description: Participant will cycle and perform cognitive training simultaneously.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycling Group
Description: Participant will cycle only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Group
Description: Participant will perform cognitive training only.
Study: NCT05480735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Multimodal prehabilitation program
Study: NCT04404101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1). EUS-FNA plus MFB
Description: The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2). EUS-FNA Alone
Description: The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
Study: NCT06511960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin (12 mg/day) intervention
Description: 12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 36 mg/day astaxanthin intervention
Description: 36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
Study: NCT04664140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QFR-based virtual PCI
Description: Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
Study: NCT05694442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipmatte K
Description: Lipmatte K contain ingredients that may hydrate and brighten the lip
Study: NCT05783570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EU307 CAR-T Cell
Description: * Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min
Study: NCT06014151

Intervention type: OTHER
Intervention: questionnaires
Description: we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
Study: NCT04664140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: angiography-based PCI
Description: PCi according to international guidelines, local protocols and practice
Study: NCT06220552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg D1, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose Radiotherapy
Description: Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W